To include your compound in the COVID-19 Resource Center, submit it here.

Exact Sciences falls on CellMax cancer diagnostic data

Exact Sciences Corp. (NASDAQ:EXAS) was off $5.27 (10%) to $47.68 on Wednesday after CellMax Life Inc. (Sunnyvale, Calif.) reported that its CellMax-CRC colorectal cancer screening test detected

Read the full 274 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE